Lower Costs for Pregabalin in Peripheral Neuropathic Pain

Share this content:
Lower Costs for Pregabalin in Peripheral Neuropathic Pain
Lower Costs for Pregabalin in Peripheral Neuropathic Pain

THURSDAY, Oct. 27, 2016 (HealthDay News) -- For patients with peripheral neuropathic pain (PNP), the adjusted cost per patient is lower for treatment with pregabalin than gabapentin, according to a study published online Sept. 27 in the Journal of Evaluation in Clinical Practice.

Antoni Sicras-Mainar, M.D., from the Papaciet Primary Care Centre in Barcelona, Spain, and colleagues conducted a retrospective observational study with electronic medical records for patients enrolled at primary care centers who initiated PNP treatment with pregabalin or gabapentin. Data were reviewed for 1,163 electronic medical records (764 for pregabalin and 399 for gabapentin).

The researchers found that the duration of treatment was slightly shorter for pregabalin than gabapentin (5.2 versus 5.5 months; P = 0.124), with mean doses of 227.4 mg and 900 mg, respectively. Per patient, the average study drug cost was higher for pregabalin than gabapentin (€214.6 versus €157.4: P < 0.001), although there was a lower cost of concomitant analgesic medication (€176.5 versus €306.7; P < 0.001). Per patient, the adjusted average total cost was lower for pregabalin treatment (€2,413 versus €3,201; P = 0.002) because of significantly lower health care costs and non-health care costs; this was due to lower use of concomitant medications, fewer primary care visits, and fewer days of sick leave.

"After loss of exclusivity of both drugs, pregabalin continued to show lower health care and non-health care costs than gabapentin in the treatment of PNP in routine clinical practice," the authors write.

Several authors disclosed financial ties to Pfizer, the manufacturer of pregabalin.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

Triple Therapy Tied to Reduced Rate of COPD Exacerbations

Triple Therapy Tied to Reduced Rate of COPD ...

Benefits seen for triple therapy with fluticasone furoate, umeclidinium, and vilanterol

Marital Status Tied to Earlier Presentation of Melanoma

Marital Status Tied to Earlier Presentation of Melanoma

Being married also tied to likelihood of undergoing SLNB in lesions with Breslow thickness >1 mm

Mild TBI May Increase Risk of Parkinson's Disease

Mild TBI May Increase Risk of Parkinson's Disease

In adjusted analyses, increased risk seen for all-severity TBI, mild TBI, moderate-severe TBI

is free, fast, and customized just for you!

Already a member?

Sign In Now »